MC2 Therapeutics and Knight Therapeutics announce launch of Wynzora® Cream in Canada
POSTED: August 20, 2026
Hørsholm, August 20, 2026 – MC2 Therapeutics, a commercial‑stage pharmaceutical company focused on topical therapies in inflammatory skin conditions, announces that its Canadian partner Knight Therapeutics Inc. (TSX: ...
READ FULL ARTICLE >
MC2 Therapeutics Announces Dosing of the first patient in the Wynzora® Phase III Clinical Trial in China
POSTED: January 6, 2026
Copenhagen, January 6, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin and Hangzhou Zhongmei Huadong ...
READ FULL ARTICLE >
Huadong and MC2 Therapeutics Announce Strategic Collaboration for Biomee® Creams in Greater China
POSTED: January 5, 2026
Hangzhou, China and Copenhagen, Denmark, December 31, 2025 – Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and MC2 Therapeutics, Ltd (“MC2”). ...
READ FULL ARTICLE >
MC2 Therapeutics Announces License and Commercialization Agreement for Wynzora® Cream in Australia
POSTED: January 4, 2026
Copenhagen, January 5, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin announces today an agreement ...
READ FULL ARTICLE >
